Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $260.50

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned an average rating of “Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $263.8750.

Several analysts have issued reports on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. TD Cowen lifted their target price on Krystal Biotech from $202.00 to $306.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Chardan Capital boosted their price target on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Citigroup raised their price objective on Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, HC Wainwright restated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KRYS. Avoro Capital Advisors LLC grew its stake in shares of Krystal Biotech by 4.4% in the 3rd quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after purchasing an additional 117,777 shares during the period. State Street Corp grew its position in Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after acquiring an additional 128,639 shares during the period. Soleus Capital Management L.P. raised its stake in Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Braidwell LP lifted its holdings in shares of Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after acquiring an additional 327,067 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Krystal Biotech by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after purchasing an additional 7,194 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 1.1%

KRYS traded up $3.03 during midday trading on Friday, reaching $285.04. The company’s stock had a trading volume of 278,797 shares, compared to its average volume of 281,682. The company has a fifty day simple moving average of $236.03 and a 200 day simple moving average of $187.68. The stock has a market cap of $8.27 billion, a P/E ratio of 42.73 and a beta of 0.46. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $295.98.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Sell-side analysts expect that Krystal Biotech will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.